Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last A$0.01 AUD
Change Today +0.001 / 9.09%
Volume 138.1M
As of 2:10 AM 05/22/15 All times are local (Market data is delayed by at least 15 minutes).

imugene ltd (IMU) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/25/14 - A$0.02
52 Week Low
12/24/14 - A$0.0080
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMUGENE LTD (IMU)

Related News

No related news articles were found.

imugene ltd (IMU) Related Businessweek News

No Related Businessweek News Found

imugene ltd (IMU) Details

Imugene Limited, an immuno-oncology biopharmaceutical company, together with its subsidiaries, engages in the research and development of novel antisense pharmaceuticals in Australia. Its lead product is HER-Vaxx, a proprietary therapeutic cancer immunotherapy that stimulates a polyclonal antibody response to HER-2/neu. HER-2/neu is a known and validated receptor over-expressed on various tumours, including gastric, breast, ovarian, lung, and pancreatic cancers. HER-Vaxx has completed a Phase I study in breast cancer and focuses on a Phase Ib/II study in gastric cancer. The company also has a research programme focused on antigen mimotopes for use in cancer vaccines. Imugene Limited is based in Armadale, Australia.

imugene ltd (IMU) Top Compensated Officers

Chief Financial Officer and Joint Company Sec...
Total Annual Compensation: A$124.8K
Head of Manufacturing & Operations, Member of...
Total Annual Compensation: A$164.8K
Joint Company Secretary
Total Annual Compensation: A$12.0K
Compensation as of Fiscal Year 2014.

imugene ltd (IMU) Key Developments

Imugene Ltd. Reports Reviewed Consolidated Earnings Results for the Half Year Ended December 31, 2014

Imugene Ltd. reported reviewed consolidated earnings results for the half year ended December 31, 2014. For the period, the company reported revenue was AUD 15,224 against AUD 6,827 for the same period last year. Other income was AUD 466,777 against nil for the same period last year. Loss before tax was AUD 1,050,873 against AUD 1,512,078 for the same period last year. Net loss for the year was AUD 1,050,873 or 0.10 cents per diluted share against AUD 1,512,078 or 0.35 cents per diluted share for the same period last year. Net cash outflows from operating activities were AUD 1,046,324 against AUD 552,976 for the same period last year. Payment for the purchase of intellectual property was AUD 463,617 against AUD 65,000 for the same period last year.

Imugene Ltd. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM

Imugene Ltd. Presents at 27th Annual ROTH Conference, Mar-10-2015 03:00 PM. Venue: The Ritz Carlton, 1 Ritz Carlton Dr, Dana Point, CA 92629, United States.

Imugene Limited Announces Appointment of Charles Walker as Managing Director and to the Board

Imugene Limited's CEO Charles Walker has been appointed as Managing Director and will join the company's board with immediate effect. Mr. Walker's election to the board comes after a successful six months since his appointment as CEO in August 2014. He has thus far overseen an important period for the company including the significant advancement of product development activities, in addition to overseeing the recent capital raising. Charles has broad and successful experience across many aspects of the biotechnology and life sciences industry. He has operational and leadership experience, a strong capital markets track record as well as a detailed scientific understanding gained from his technical background in pharmacology.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMU:AU A$0.01 AUD +0.001

IMU Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMU.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMU Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 12.0x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 12.3x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMUGENE LTD, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at